pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 20·1 min read
save

STAT readers split on spelling of "health care" as industry leans toward single word

Jun 20, 2026·read at STAT ↗Neutral

STAT recently asked its audience whether to write the term as two words or one. Roughly 60% of respondents favored one spelling over the other.

The discussion highlights a subtle but growing trend in medical communication, with many industry voices adopting the single-word form even though the traditional two-word version has long been standard.

The commentary, written by First Opinion editor Torie Bosch and drawn from a podcast interview with Sarah Mupo, invites readers to consider how such linguistic choices can shape perceptions of health care.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Why the space in ‘health care’ matters”

read at STAT ↗
2,807 words · retrieved Jun 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Boundless Bio, Inc.
topics
Ophthalmology3GLP-1 receptorOncology

related stories

  • Sep 28STAT+: AbbVie wins FDA nod for Parkinson’s pillSTAT
  • Sep 18Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese miceFierce Biotech
  • Aug 24Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismFierce Biotech
  • Aug 18STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle massSTAT
  • Aug 14Skye and Redx form new entity with $125M to advance fibrosis assetsFierce Biotech